ClinicalTrials.Veeva

Menu

Dextenza for Post-operative Treatment of Pterygium (PERSIST)

B

Brandon Eye Associates, PA

Status and phase

Active, not recruiting
Phase 4

Conditions

Pterygium of Both Eyes

Treatments

Drug: Prednisolone Acetate
Drug: Intracanalicular Dexamethasone, (0.4 mg) Insert

Study type

Interventional

Funder types

Other

Identifiers

NCT04351737
PERSIST Study

Details and patient eligibility

About

DEXTENZA for the Treatment of Post-Surgical Pain and Inflammation Compared to Standard of Care Topical Cortico-steroid Treatment in Patients who Undergo Bilateral Pterygium Surgery

Full description

In patients who undergo bilateral pterygium surgery, eyes will be randomized to receive either DEXTENZA at baseline, Month 1 and Month 2 or prednisolone x 3 months. Both eyes will receive antibiotic drops four times per day for two weeks and Maxitrol ointment at bedtime for two weeks following surgery.

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: patients with bilateral pterygium -

Exclusion Criteria: none

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Pterygium patients
Experimental group
Description:
patients with bilateral pterytium
Treatment:
Drug: Intracanalicular Dexamethasone, (0.4 mg) Insert
Drug: Prednisolone Acetate

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems